Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chlamydia pneumoniae infection promotes the transmigration of monocytes through human brain endothelial cells.

Journal of neuroscience research·2003
Same author

Prolonged E55+ retrovirus expression in aged mice is associated with a decline in the anti-virus immune response.

Virology·2002
Same author

Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B.

Protein science : a publication of the Protein Society·2001
Same author

Structure and function of procollagen C-proteinase (mTolloid) domains determined by protease digestion, circular dichroism, binding to procollagen type I, and computer modeling.

Biochemistry·2000
Same author

Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis.

Blood·2000
Same author

Genetic regulation of long-term nonprogression in E-55+ murine leukemia virus infection in mice.

Journal of virology·1999

Related Experiment Video

Updated: Jul 26, 2026

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

Rational design of cytotoxic T-cell inhibitors.

A P Tretiakova1, C S Little, K J Blank

  • 1Department of Pathology and Laboratory Medicine, Cancer Center, School of Medicine, MCP Hahnemann University, Philadelphia, PA 19102, USA.

Nature Biotechnology
|September 6, 2000
PubMed
Summary

Researchers designed small molecules to block T-cell activation by targeting CD8 and MHC class I interactions. One peptide analog inhibited cytotoxic T lymphocyte (CTL) responses and viral clearance in mice.

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Jul 26, 2026

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Area of Science:

  • Immunology
  • Structural Biology
  • Drug Design

Background:

  • T-cell activation relies on interactions between CD8 and Major Histocompatibility Complex (MHC) class I molecules.
  • Blocking these interactions is a strategy to modulate immune responses, particularly in cytotoxic T lymphocyte (CTL) activation.
  • Designing small molecules to mimic protein surfaces presents a challenge in drug discovery.

Purpose of the Study:

  • To design novel low-molecular-weight surface mimetics targeting the CD8/MHC class I interface.
  • To investigate the potential of these mimetics to inhibit T-cell activation and associated immune responses.
  • To assess the in vivo efficacy and selectivity of designed analogs.

Main Methods:

  • Utilized the crystal structure of CD8/MHC class I complex as a template for de novo design.
  • Synthesized conformationally restrained peptide analogs based on the CD8 alpha-chain surface.
  • Assessed analog activity using primary allogeneic CTL assays and CD4-dependent mixed lymphocyte reaction (MLR).
  • Evaluated in vivo effects on viral clearance and CTL responses in murine models.

Main Results:

  • A conformationally restrained peptide analog demonstrated dose-dependent inhibition of allogeneic CTL assays.
  • The analog selectively inhibited CD8-dependent T-cell responses without affecting CD4-dependent MLR.
  • Modifications in side chain composition fine-tuned the analog's activity.
  • In vivo administration prevented CD8-dependent viral clearance and selectively inhibited antiviral CTL responses in mice.

Conclusions:

  • De novo design of low-molecular-weight mimetics targeting CD8/MHC class I interactions is feasible.
  • Designed peptide analogs can selectively inhibit CTL responses.
  • These findings support the development of small molecule inhibitors for modulating T-cell mediated immunity.